SCHEMBL14246752

SCHEMBL14246752

Cc1c(Cc2c(Cl)cccc2Cl)c(=O)[nH]c2cc(O)cc(O)c12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 4/20 0.45
POLB P06746 1/20 0.40
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
DDO Q99489 2/20 0.39
ALOX5 P09917 1/20 0.38
LMNA P02545 1/20 0.37
EGFR P00533 1/20 0.37
SRC P12931 1/20 0.37
GRIN2D O15399 1/20 0.36
GRIN3B O60391 1/20 0.36
GRIN1 Q05586 1/20 0.36
GRIN2A Q12879 1/20 0.36
GRIN2B Q13224 1/20 0.36
GRIN2C Q14957 1/20 0.36
GRIN3A Q8TCU5 1/20 0.36
EEF2K O00418 1/20 0.36
PLK4 O00444 1/20 0.36
IKBKB O14920 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14246738 0.92 LMNA (0.48) DAOALDH1A1MAPTDDOLMNA
SCHEMBL14246830 0.84 ALDH1A1 (0.46) DAOKDM4EALDH1A1MAPTALOX5
SCHEMBL6584194 0.82 ALDH1A1 (0.58) POLBKDM4EALDH1A1MAPTMEN1
SCHEMBL14317182 0.82 NR3C1 (0.40) DAOKDM4EALDH1A1MAPTEGFR
SCHEMBL15931678 0.82 KDM4E (0.38) DAOKDM4EALDH1A1MAPTDDO
SCHEMBL15931670 0.81 KDM4E (0.47) DAOKDM4EALDH1A1MAPTMEN1
SCHEMBL15931677 0.80 KDM4E (0.47) DAOKDM4EALDH1A1MAPTDDO
SCHEMBL3344690 0.78 SMN1; SMN2 (0.49) DAOKDM4EALDH1A1ALOX5NR3C1
SCHEMBL14317221 0.78 ALDH1A1 (0.44) DAOKDM4EALDH1A1MAPTDDO
SCHEMBL14246747 0.75 KDM4E (0.70) POLBKDM4EALDH1A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9334256-B2 Agents and methods for treating ischemic and other diseases NONO INC. (CA) 2016-05-10 US disclosed
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases NONO INC. (CA) 2014-08-07 US disclosed
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases NONO INC. (CA) 2014-08-07 US disclosed
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases NONO INC. (CA) 2014-08-07 US disclosed
EP-2720695-A2 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES NoNO Inc. (CA) 2014-04-23 EP disclosed
WO-2012174488-A2 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES NONO, INC. (CA) 2012-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases TRPM7, TRPM8, TRPM5 DAO 3711/4885POLB 3840/4885KDM4E 4656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.